|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PART1 |
Gene summary for PART1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PART1 | Gene ID | 25859 |
| Gene name | prostate androgen-regulated transcript 1 | |
| Gene Alias | NCRNA00206 | |
| Cytomap | 5q12.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25859 | PART1 | LZE4T | Human | Esophagus | ESCC | 9.08e-07 | 2.61e-01 | 0.0811 |
| 25859 | PART1 | LZE24T | Human | Esophagus | ESCC | 4.82e-08 | 4.08e-01 | 0.0596 |
| 25859 | PART1 | P1T-E | Human | Esophagus | ESCC | 2.17e-05 | 2.74e-01 | 0.0875 |
| 25859 | PART1 | P2T-E | Human | Esophagus | ESCC | 3.45e-08 | -1.23e-01 | 0.1177 |
| 25859 | PART1 | P4T-E | Human | Esophagus | ESCC | 1.06e-16 | 4.84e-01 | 0.1323 |
| 25859 | PART1 | P5T-E | Human | Esophagus | ESCC | 1.08e-02 | -2.14e-01 | 0.1327 |
| 25859 | PART1 | P8T-E | Human | Esophagus | ESCC | 1.27e-12 | 4.53e-01 | 0.0889 |
| 25859 | PART1 | P9T-E | Human | Esophagus | ESCC | 3.42e-15 | 5.13e-01 | 0.1131 |
| 25859 | PART1 | P10T-E | Human | Esophagus | ESCC | 4.62e-09 | -3.40e-02 | 0.116 |
| 25859 | PART1 | P12T-E | Human | Esophagus | ESCC | 5.98e-14 | 3.92e-01 | 0.1122 |
| 25859 | PART1 | P15T-E | Human | Esophagus | ESCC | 3.64e-04 | 4.21e-03 | 0.1149 |
| 25859 | PART1 | P16T-E | Human | Esophagus | ESCC | 3.47e-09 | 1.29e-01 | 0.1153 |
| 25859 | PART1 | P22T-E | Human | Esophagus | ESCC | 2.25e-03 | -1.02e-01 | 0.1236 |
| 25859 | PART1 | P23T-E | Human | Esophagus | ESCC | 5.55e-14 | 4.83e-01 | 0.108 |
| 25859 | PART1 | P26T-E | Human | Esophagus | ESCC | 1.09e-07 | -7.16e-03 | 0.1276 |
| 25859 | PART1 | P27T-E | Human | Esophagus | ESCC | 1.50e-23 | 4.10e-01 | 0.1055 |
| 25859 | PART1 | P28T-E | Human | Esophagus | ESCC | 2.68e-03 | -2.12e-01 | 0.1149 |
| 25859 | PART1 | P30T-E | Human | Esophagus | ESCC | 1.22e-06 | 2.40e-01 | 0.137 |
| 25859 | PART1 | P31T-E | Human | Esophagus | ESCC | 3.75e-03 | -2.21e-01 | 0.1251 |
| 25859 | PART1 | P37T-E | Human | Esophagus | ESCC | 2.51e-02 | -1.02e-01 | 0.1371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |